A considerable body of evidence suggests that Fc-dependent functions improve the capacity of broadly neutralizing antibodies (BnAbs) to protect against and control HIV-1 infection. This phenomenon, however, has not been formally tested in robust cell-associated macaque simian-human immunodeficiency virus (SHIV) models with newer-generation BnAbs. We studied both the WT BnAb PGT121 and a LALA mutant of PGT121 (which has impaired Fc-dependent functions) for their ability to protect pigtail macaques from an i.v. high-dose cell-associated SHIVSF162P3 challenge. We found that both WT and LALA PGT121 completely protected all 12 macaques studied. Further, partial depletion of NK cells, key mediators of Fc-dependent functions, did not abrogate the protective efficacy of PGT121 in 6 macaques. Additionally, in animals with established SHIVSF162P3 infection, SHIV viremia levels were equally rapidly reduced by LALA and WT PGT121. Our studies suggest that the potent neutralizing capacity of PGT121 renders the Fc-dependent functions of the Ab at least partially redundant. These findings have implications for Ab-mediated protection from and control of HIV-1 infection.
Matthew S. Parsons, Wen Shi Lee, Anne B. Kristensen, Thakshila Amarasena, Georges Khoury, Adam K. Wheatley, Arnold Reynaldi, Bruce D. Wines, P. Mark Hogarth, Miles P. Davenport, Stephen J. Kent
Title and authors | Publication | Year |
---|---|---|
SIV monoclonal antibody administration spanning treatment interruption in macaques delays viral rebound and selects escape variants
King HA, Brammer D, Lewitus E, Fennessey CM, Manalang KM, Shrader HR, Andrew S, Kuri P, Lind M, Pham P, Sanders-Buell E, Bai H, Mason R, Song K, McCarthy E, Helmold Hait S, Todd JP, Pegu A, Foulds KE, Lifson JD, Keele BF, Rolland M, Roederer M, Bolton DL |
Proceedings of the National Academy of Sciences of the United States of America | 2025 |
Afucosylated broadly neutralizing antibodies targeting the HIV envelope elicit enhanced NK-cell–mediated cytotoxicity against HIV-infected CD4+ T-cell and macrophage targets
Wilhelm O, Jordan C, Kek H, Brunton-O\u2019Sullivan MM, Rikard-Bell L, Ramanathan P, Chung AW, Poumbourios P, Wines BD, Jaworowski A, Hearps AC |
Journal of Leukocyte Biology | 2025 |
A potent and broad CD4 binding site neutralizing antibody with strong ADCC activity from a Chinese HIV-1 elite neutralizer.
Wang Y, Ji P, Liu Q, Jia N, Ma Y, Yuan T, Rehati P, Chen J, Wen Y, Wu F, Huang J |
Cell discovery | 2025 |
Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention
Becerra JC, Hitchcock L, Vu K, Gach JS |
Microbial Cell | 2024 |
Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing
de Taeye SW, Schriek AI, Umotoy JC, Grobben M, Burger JA, Sanders RW, Vidarsson G, Wuhrer M, Falck D, Kootstra NA, van Gils MJ |
Communications biology | 2024 |
Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIVAD8-EO infection
Dias J, Fabozzi G, Fourati S, Chen X, Liu C, Ambrozak DR, Ransier A, Laboune F, Hu J, Shi W, March K, Maximova AA, Schmidt SD, Samsel J, Talana CA, Ernste K, Ko SH, Lucas ME, Radecki PE, Boswell KL, Nishimura Y, Todd JP, Martin MA, Petrovas C, Boritz EA, Doria-Rose NA, Douek DC, Sékaly RP, Lifson JD, Asokan M, Gama L, Mascola JR, Pegu A, Koup RA |
Nature Communications | 2024 |
Mechanisms of sterilizing immunity provided by an HIV-1 neutralizing antibody against mucosal infection
Richel E, Cordsmeier A, Bauer L, Fraedrich K, Vestweber R, Roshani B, Stolte-Leeb N, Ensser A, Stahl-Hennig C, Überla K |
PLOS Pathogens | 2024 |
Phenotypic and functional characterization of pharmacologically expanded Vγ9Vδ2 T cells in pigtail macaques
Barber-Axthelm IM, Wragg KM, Esterbauer R, Amarasena TH, Barber-Axthelm VR, Wheatley AK, Gibbon AM, Kent SJ, Juno JA |
iScience | 2023 |
Antiviral neutralizing antibodies: from in vitro to in vivo activity
Burton DR |
Nature reviews. Immunology | 2023 |
Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure
Karunasinee Suphaphiphat, Delphine Desjardins, Valérie Lorin, Nastasia Dimant, Kawthar Bouchemal, Laetitia Bossevot, Maxence Galpin-Lebreau, Nathalie Dereuddre-Bosquet, Hugo Mouquet, Roger Le Grand, Mariangela Cavarelli |
Nature Communications | 2023 |
Complement contributes to antibody-mediated protection against repeated SHIV challenge
Goldberg BS, Spencer DA, Pandey S, Ordonez T, Barnette P, Yu Y, Gao L, Dufloo J, Bruel T, Schwartz O, Ackerman ME, Hessell AJ |
Proceedings of the National Academy of Sciences | 2023 |
Antibody-dependent cellular cytotoxicity, infected cell binding and neutralization by antibodies to the SIV envelope glycoprotein.
Grunst MW, Ladd RA, Clark NM, Gil HM, Klenchin VA, Mason R, Franchini G, Roederer M, Evans DT |
PLoS pathogens | 2023 |
Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques
Haycroft ER, Damelang T, Lopez E, Rodgers MA, Wines BD, Hogarth M, Ameel CL, Kent SJ, Scanga CA, O'Connor SL, Chung AW |
IBMS BoneKEy | 2023 |
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
Tieu HV, Karuna S, Huang Y, Sobieszczyk ME, Zheng H, Tomaras GD, Montefiori DC, Shen M, DeRosa S, Cohen K, Isaacs MB, Regenold S, Heptinstall J, Seaton KE, Sawant S, Furch B, Pensiero M, Corey L, Bar KJ |
Vaccine | 2023 |
Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis
D Spencer, B Goldberg, S Pandey, T Ordonez, J Dufloo, P Barnette, W Sutton, H Henderson, R Agnor, L Gao, T Bruel, O Schwartz, N Haigwood, M Ackerman, A Hessell |
Nature Communications | 2022 |
Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice
C Hioe, G Li, X Liu, O Tsahouridis, X He, M Funaki, J Klingler, A Tang, R Feyznezhad, D Heindel, X Wang, D Spencer, G Hu, N Satija, J Prévost, A Finzi, A Hessell, S Wang, S Lu, B Chen, S Zolla-Pazner, C Upadhyay, R Alvarez, L Su, D Douek |
PLoS pathogens | 2022 |
Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses
P Klasse, J Moore, G Silvestri |
Journal of virology | 2022 |
Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells
J Dufloo, C Planchais, S Frémont, V Lorin, F Guivel-Benhassine, K Stefic, N Casartelli, A Echard, P Roingeard, H Mouquet, O Schwartz, T Bruel |
Nature Communications | 2022 |
A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 delta infection
N Routhu, S Gangadhara, L Lai, M Gardner, K Floyd, A Shiferaw, Y Bartsch, S Fischinger, G Khoury, S Rahman, S Stampfer, A Schaefer, S Jean, C Wallace, R Stammen, J Wood, J Cohen, T Nagy, M Parsons, L Gralinski, P Kozlowski, G Alter, M Suthar, R Amara |
Science Immunology | 2022 |
Assessment of Fcγ receptor-dependent binding of influenza hemagglutinin vaccine-induced antibodies in a non-human primate model
Masuta Y, Takahama S, Nogimori T, Moriyama S, Takahashi Y, Yamamoto T |
iScience | 2022 |
Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice.
Brady JM, Phelps M, MacDonald SW, Lam EC, Nitido A, Parsons D, Boutros CL, Deal CE, Garcia-Beltran WF, Tanno S, Natarajan H, Ackerman ME, Vrbanac VD, Balazs AB |
Science Translational Medicine | 2022 |
HIV-1 Vpu restricts Fc-mediated effector functions in vivo
Prévost J, Anand SP, Rajashekar JK, Zhu L, Richard J, Goyette G, Medjahed H, Gendron-Lepage G, Chen HC, Chen Y, Horwitz JA, Grunst MW, Zolla-Pazner S, Haynes BF, Burton DR, Flavell RA, Kirchhoff F, Hahn BH, Smith AB III, Pazgier M, Nussenzweig MC, Kumar P, Finzi A |
Cell Reports | 2022 |
Are Fc Gamma Receptor Polymorphisms Important in HIV-1 Infection Outcomes and Latent Reservoir Size?
H Lamptey, EY Bonney, B Adu, GB Kyei |
Frontiers in immunology | 2021 |
Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic
DA Spencer, MB Shapiro, NL Haigwood, AJ Hessell |
Frontiers in public health | 2021 |
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
R Duerr, KM Crosse, AM Valero-Jimenez, M Dittmann |
Microorganisms | 2021 |
Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection
BM Gunn, S Bai |
Human Vaccines & Immunotherapeutics | 2021 |
Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features
HD Cheng, KG Dowell, C Bailey-Kellogg, BA Goods, JC Love, G Ferrari, G Alter, J Gach, DN Forthal, GK Lewis, K Greene, H Gao, DC Montefiori, ME Ackerman |
Retrovirology | 2021 |
Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies
T Noy-Porat, A Edri, R Alcalay, E Makdasi, D Gur, M Aftalion, Y Evgy, A Beth-Din, Y Levy, E Epstein, O Radinsky, A Zauberman, S Lazar, S Yitzhaki, H Marcus, A Porgador, R Rosenfeld, O Mazor |
Antibodies | 2021 |
Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies
JM Edwards, B Heydarchi, G Khoury, NA Salazar-Quiroz, CA Gonelli, B Wines, PM Hogarth, AB Kristensen, MS Parsons, DF Purcell, F Kirchhoff |
Journal of virology | 2021 |
Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity
BS Goldberg, CI Kaku, J Dufloo, T Bruel, O Schwartz, DA Spencer, AJ Hessell, ME Ackerman, M Caskey, L Pirofski |
mBio | 2021 |
TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure
CT Hvilsom, OS Søgaard |
Frontiers in immunology | 2021 |
Broadly Neutralizing Antibodies for HIV-1 Prevention
SR Walsh, MS Seaman |
Frontiers in immunology | 2021 |
Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcγRIIb on Liver Sinusoidal Endothelial Cells by Endocytosis
JM Turman, AM Cheplowitz, C Tiwari, T Thomas, D Joshi, M Bhat, Q Wu, E Pong, SY Chu, DE Szymkowski, A Sharma, S Seveau, JM Robinson, JJ Kwiek, D Burton, MV Rajaram, J Kim, L Hangartner, LP Ganesan |
Journal of immunology (Baltimore, Md. : 1950) | 2021 |
Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates
L Hangartner, D Beauparlant, E Rakasz, R Nedellec, N Hozé, K McKenney, MA Martins, GE Seabright, JD Allen, AM Weiler, TC Friedrich, RR Regoes, M Crispin, DR Burton |
Science Translational Medicine | 2021 |
Anatomic Distribution of Intravenously Injected IgG Takes Approximately 1 Week to Achieve Stratum Corneum Saturation in Vaginal Tissues
AM Carias, JR Schneider, P Madden, R Lorenzo-Redondo, M Araínga, A Pegu, GC Cianci, D Maric, F Villinger, JR Mascola, RS Veazey, TJ Hope |
Journal of immunology (Baltimore, Md. : 1950) | 2021 |
Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure
MS Parsons, AB Kristensen, KJ Selva, WS Lee, T Amarasena, R Esterbauer, AK Wheatley, BR Bavinton, AD Kelleher, AE Grulich, G Khoury, JA Juno, SJ Kent |
EBioMedicine | 2021 |
Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis
M Phelps, AB Balazs |
Frontiers in immunology | 2021 |
Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells
SP Anand, S Ding, WD Tolbert, J Prévost, J Richard, HM Gil, G Gendron-Lepage, WF Cheung, H Wang, R Pastora, H Saxena, W Wakarchuk, H Medjahed, BD Wines, M Hogarth, GM Shaw, MA Martin, DR Burton, L Hangartner, DT Evans, M Pazgier, D Cossar, MD McLean, A Finzi, V Simon |
Journal of virology | 2021 |
Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121
WS Lee, A Reynaldi, T Amarasena, MP Davenport, MS Parsons, SJ Kent |
Frontiers in immunology | 2021 |
A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination
MM Lemke, MR McLean, CY Lee, E Lopez, ER Bozich, S Rerks-Ngarm, P Pitisuttithum, S Nitayaphan, S Kratochvil, BD Wines, PM Hogarth, SJ Kent, AW Chung, KB Arnold |
Cell reports. Medicine | 2021 |
Improved Killing of HIV-infected Cells Using Three Neutralizing and Non-neutralizing Antibodies
Marina Tuyishime, Carolina Garrido, Shalini Jha, Matthew Moeser, Dieter Mielke, Celia LaBranche, David Montefiori, Barton F. Haynes, Sarah B. Joseph, David M. Margolis, Guido Ferrari |
Journal of Clinical Investigation | 2020 |
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
WS Lee, AK Wheatley, SJ Kent, BJ DeKosky |
Nature Microbiology | 2020 |
Recent insights into Fc-mediated effector responses to HIV-1
MC Carpenter, ME Ackerman |
Current Opinion in HIV and AIDS | 2020 |
Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo
P Wang, MR Gajjar, J Yu, NN Padte, A Gettie, JL Blanchard, K Russell-Lodrigue, LE Liao, AS Perelson, Y Huang, DD Ho |
Proceedings of the National Academy of Sciences | 2020 |
Relationships between Neutralization, Binding, and ADCC of Broadly Neutralizing Antibodies against Reservoir HIV
Y Ren, M Korom, AR Ward, R Truong, D Chan, SH Huang, CM Kovacs, E Benko, JT Safrit, J Lee, H Garbán, R Lynch, RB Jones, G Silvestri |
Journal of virology | 2020 |
Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques
Z Li, M Khanna, SL Grimley, P Ellenberg, CA Gonelli, WS Lee, TH Amarasena, AD Kelleher, DF Purcell, SJ Kent, C Ranasinghe |
Scientific Reports | 2020 |
Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
MB Shapiro, T Cheever, DC Malherbe, S Pandey, J Reed, ES Yang, K Wang, A Pegu, X Chen, D Siess, D Burke, H Henderson, R Lewinsohn, M Fischer, JJ Stanton, MK Axthelm, C Kahl, B Park, AD Lewis, JB Sacha, JR Mascola, AJ Hessell, NL Haigwood |
Nature Communications | 2020 |
Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody
M Asokan, J Dias, C Liu, A Maximova, K Ernste, A Pegu, K McKee, W Shi, X Chen, C Almasri, W Promsote, DR Ambrozak, L Gama, J Hu, DC Douek, JP Todd, JD Lifson, S Fourati, RP Sekaly, AR Crowley, ME Ackerman, SH Ko, D Kilam, EA Boritz, LE Liao, K Best, AS Perelson, JR Mascola, RA Koup |
Proceedings of the National Academy of Sciences | 2020 |
Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1
GK Lewis, ME Ackerman, G Scarlatti, C Moog, M Robert-Guroff, SJ Kent, J Overbaugh, RK Reeves, G Ferrari, B Thyagarajan |
Frontiers in immunology | 2019 |
Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses
MZ Tay, K Wiehe, J Pollara |
Frontiers in immunology | 2019 |
Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections
SP Anand, A Finzi |
Human vaccines | 2019 |
A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities
JR Schneider, X Shen, C Orlandi, T Nyanhete, S Sawant, AM Carias, AD Smith, NL Kelleher, RS Veazey, GK Lewis, GD Tomaras, TJ Hope, G Silvestri |
Journal of virology | 2019 |
Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization
B Su, S Dispinseri, V Iannone, T Zhang, H Wu, R Carapito, S Bahram, G Scarlatti, C Moog |
Frontiers in immunology | 2019 |
Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function
AR Crowley, ME Ackerman |
Frontiers in immunology | 2019 |
Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1:
S Pittala, KS Morrison, ME Ackerman |
Current Opinion in HIV and AIDS | 2019 |
V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers
R Duerr, MK Gorny |
Human vaccines | 2019 |
Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly Active Antibody-Dependent Cell Cytotoxicity
H Sojar, S Baron, JT Sullivan, M Garrett, MM van Haaren, J Hoffman, J Overbaugh, BJ Doranz, MD Hicar, F Kirchhoff |
Journal of virology | 2019 |
Antibody responses to the HIV-1 envelope high mannose patch
Christine N Daniels, Kevin O Saunders |
Advances in immunology | 2019 |
Blocking HIV-1 replication: are Fc-Fcγ receptor interactions required?
Don Forthal, Andres Finzi |
Journal of Clinical Investigation | 2018 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |